Survival Outcomes of Head and Neck Neuroendocrine Carcinoma: A Systematic Review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 42469919.
- Also identified by DOI 10.1002/hed.70402.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This systematic review investigated pathological, oncological, and survival outcomes of Head and neck neuroendocrine carcinoma (HNNEC). Three independent investigators conducted a PRISMA-compliant literature search. Primary outcomes included tumor stage, overall survival (OS), disease-free survival, recurrence, metastasis, and therapeutic strategies. The most common locations were the larynx (n = 1041), sinonasal tract (n = 917), and oropharynx (n = 366), mostly cT2/cT4 and cN0/cN2. Small-cell carcinoma predominated (n = 2334). Laryngeal tumors were preferentially treated by surgery plus radiotherapy, sinonasal/nasopharyngeal tumors by chemoradiotherapy, and salivary tumors by surgery with adjuvant therapy. Surgical cohorts achieved 5-year OS of 33.0%-73.9%, and multimodal CRT-plus-surgery 57.2%-61.0%. Laryngeal and mucosal tumors had more favorable outcomes than sinonasal/salivary localizations; well/moderately-differentiated carcinoids outperformed poorly-differentiated and small-cell variants (median OS < 24 months). HNNEC survival strongly depends on histology, site, and treatment modality. Substantial therapeutic heterogeneity reflects the lack of guidelines, highlighting the need for standardized, histology- and site-specific management recommendations.